Dow Jones
38.085,80 -375,12 (-0,98%) Nasdaq
15.611,76 -100,99 (-0,64%) Nikkei 225
37.944,69 +316,21 (+0,84%) EUR/USD
1,0725 -0,0008 (-0,08%) Bitcoin EUR
59.961,03 -4,94 (-0,01%) CMC Crypto 200
1.386,82 +4,24 (+0,31%)
Zentalis Pharmaceuticals, Inc. (ZNTL)
Dopo ore:
| Chiusura precedente | 11,77 |
| Aperto | 11,18 |
| Denaro | 10,94 x 200 |
| Lettera | 11,05 x 100 |
| Min-Max giorno | 10,39 - 11,28 |
| Intervallo di 52 settimane | 9,56 - 31,46 |
| Volume | |
| Media Volume | 835.250 |
| Capitalizzazione | 779,498M |
| Beta (5 anni mensile) | 1,73 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -4,47 |
| Prossima data utili | 08 mag 2024 - 13 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 34,40 |
GlobeNewswireZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK and SAN DIEGO, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancer, today announced that on October 2, 2023, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 101,375 shares of the Company’s common stock to four
- GlobeNewswire
Zentalis Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
NEW YORK and SAN DIEGO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Kimberly Blackwell, M.D., Chief Executive Officer of Zentalis, will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on Wednesday, September 13, 2023
- GlobeNewswire
Zentalis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates
Azenosertib monotherapy achieved an ORR of 36.8% in heavily pretreated platinum-resistant ovarian cancer and USC patients who received intermittent dosing Identified azenosertib monotherapy RP2D, which more than doubles exposure levels, maintains safety and improves tolerability with no treatment-related discontinuations Presented positive Phase 1b azenosertib + chemotherapy data in ovarian cancer at ASCO, demonstrating encouraging anti-tumor activity and strong tolerability profile with intermi
